What happened in optometry this week: September 30 - October 4
Catch up on what happened in optometry during the week of September 30-October 4.
Catch up with what Optometry Times shared this week:
Aldeyra Therapeutics resubmits NDA for reproxalap for DED signs and symptoms treatment
By Jordana Joy, Associate Editor
Biotechnology company Aldeyra Therapeutics announced the resubmission of the New Drug Application (NDA) to the US FDA for the investigational new drug candidate topical ocular reproxalap, intended for the treatment of signs and symptoms of dry eye disease (DED).1 The application was resubmitted with a draft label reflecting acute activity in reducing dry eye symptoms in a dry eye chamber trial, chronic activity in reducing dry eye symptoms in a field trial, and acute activity in reducing ocular redness in 2 dry eye chamber trials, according to a news release. Previously disclosed positive results from a completed DED symptom trial were also submitted after being requested by the FDA following review of the previously submitted NDA.1
Enrollment complete of phase 2b of SIGLEC study to assess safety and efficacy of AVD-104 for GA secondary to AMD
By Lynda Charters
Aviceda Therapeutics has completed enrollment of the phase 2b trial of the SIGLEC Study. The study will assess the safety and efficacy of AVD-104, the company’s formulation designed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
AVD-104 is described by the company as an optimized intravitreal glycomimetic nanoparticle designed to increase the efficacy and safety of GA treatment via its differentiated dual mechanism of action that works farther upstream to inhibit macrophage and complement cascade amplification.
Study reports the majority of MiYOSMART spectacle lens users continue use for as long as 8 years
By Jordana Joy, Associate Editor
A new clinical study evaluating long-term myopia control effect and user experience in patients wearing Defocus Incorporated Multiple Segments (DIMS)-outfitted MiYOSMART spectacle lenses found that a significant amount of said patients continued to wear the lenses for as long as 8 years. Findings from the 8-year follow-up clinical study were presented by HOYA Vision Care at the 60th International Myopia Conference 2024 in Sanya, China, according to a news release.
Bausch + Lomb launches digital marketplace for eye care practices and patients in US
By Jordana Joy, Associate Editor
Bausch + Lomb has now launched Opal, a digital e-commerce marketplace designed to maximize efficiencies for eye care practices that is also available to their patients, in the US.1 The marketplace will streamline the ordering process for Bausch + Lomb contacts lenses, with other select OTC products to be added in the coming months, according to a news release.
Researchers find color vision deficiency may impact choroidal diagnosis
By Lynda Charters
A team of international investigators has found that color vision deficiency (CVD) may interfere with an eye care provider’s ability to differentiate between choroidal melanoma and choroidal nevus.1
Yacoub A. Yousef, MD, is the first study author and an ocular oncologist in the Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan.
